Land: Israel
Språk: engelsk
Kilde: Ministry of Health
DASATINIB
NOVARTIS ISRAEL LTD
L01XE06
FILM COATED TABLETS
DASATINIB 20 MG
PER OS
Not required
LEK PHARMACEUTICALS D.D., SLOVENIA
DASATINIB
Treatment of adult patients with : Newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase. Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.
2023-05-10
PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS’ REGULATIONS )PREPARATIONS( - 1986 This medicine is dispensed with a doctor’s prescription only Dasatinib Sandoz ® 20 mg Film-coated tablets Dasatinib Sandoz ® 50 mg Film-coated tablets Dasatinib Sandoz ® 70 mg Film-coated tablets COMPOSITION: Each tablet contains: dasatinib 20 mg COMPOSITION: Each tablet contains: dasatinib 50 mg COMPOSITION: Each tablet contains: dasatinib 70 mg Dasatinib Sandoz ® 100 mg Film-coated tablets Dasatinib Sandoz ® 140 mg Film-coated tablets COMPOSITION: Each tablet contains: dasatinib 100 mg COMPOSITION: Each tablet contains: dasatinib 140 mg Inactive ingredients and allergens: see section 2 under ‘Important information about some of this medicine’s ingredients’, and section 6 ‘Additional information’. Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist. This medicine has been prescribed to treat your illness. Do not pass it on to others. It may harm them, even if it seems to you that their illness is similar to yours. Dasatinib Sandoz is not intended for use in children and adolescents under the age of 18. There is limited experience with the use of dasatinib in this age group. 1. What is this medicine intended for? Dasatinib Sandoz is a medicine intended for treatment of adult patients with: Newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia )CML( in the chronic phase. Chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate. Philadelphia chromosome positive acute lymphoblastic leukaemia )ALL( and lymphoid blast CML with resistance or intolerance to prior therapy. THERAPEUTIC GROUP: Protein kinase inhibitors. 2. Before using this medicine Do not use this medicine if: you are sensitive )allergic( to the active ingredient )dasatinib( or to any of the other ingredients in this med Les hele dokumentet